Program
lanoracopan
Its studies are mostly in Hemoglobinuria, Paroxysmal · Hepatic Insufficiency · Glomerulonephritis, IGA, led by Wuhan Createrna Science and Technology.
Furthest: phase 3, since Apr 9, 202511 company-led studies, 6 open or runningNext primary completion: Dec 30, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Wuhan Createrna Science and Technology | 116 open or running | phase 3since Apr 9, 2025 | Nov 30, 2022 | Dec 30, 2026phase 3 · NCT06933914 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 30, 2022First study: phase 1 study in Hemoglobinuria, ParoxysmalFirst studyNCT05642585 · 63 enrolled · China
- Apr 13, 20232 phase 1 studies in Hemoglobinuria, ParoxysmalNCT05828485, NCT05828472
- Sep 11, 2023Phase 2 study in Hemoglobinuria, ParoxysmalNCT06050226 · 34 enrolled · China
- Nov 10, 2023Phase 2 study in Hemoglobinuria, ParoxysmalNCT06134414 · 40 planned
- Aug 2, 2024Phase 1 study in Hemoglobinuria, ParoxysmalNCT06543459 · 16 planned · China
- Nov 11, 2024Phase 2 study in Glomerulonephritis, IGANCT06687174 · 72 planned · China
- Apr 9, 20253 phase 3 studies in Hemoglobinuria, ParoxysmalNCT06932471, NCT06932744, NCT06933914
- May 9, 2026Phase 1 study in Hepatic InsufficiencyNCT07625618 · 24 enrolled · China
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT06933914
- Jul 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT06134414
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07625618Hepatic Insufficiency · China | 1 | Completed | Dec 28, 2024 | 24 |
| NCT06933914Hemoglobinuria, Paroxysmal · China | 3 | Recruiting | Dec 30, 2026 | 120 |
| NCT06932744Hemoglobinuria, Paroxysmal · China | 3 | Recruiting | Dec 30, 2025 | 66 |
| NCT06932471Hemoglobinuria, Paroxysmal · China | 3 | Recruiting | Dec 30, 2025 | 20 |
| NCT06687174Glomerulonephritis, IGA · China | 2 | Not yet recruiting | Jun 15, 2026 | 72 |
| NCT06543459Hemoglobinuria, Paroxysmal · China | 1 | Not yet recruiting | Sep 27, 2024 | 16 |
| NCT06134414Hemoglobinuria, Paroxysmal | 2 | Not yet recruiting | Jul 2027 | 40 |
| NCT06050226Hemoglobinuria, Paroxysmal · China | 2 | Completed | Apr 30, 2024 | 34 |
| NCT05828485Hemoglobinuria, Paroxysmal · China | 1 | Completed | Oct 23, 2022 | 12 |
| NCT05828472Hemoglobinuria, Paroxysmal · China | 1 | Completed | Jun 30, 2023 | 40 |
| NCT05642585Hemoglobinuria, Paroxysmal · China | 1 | Completed | Jun 4, 2023 | 63 |
How it is read
Names in the registry
- “MY008211A tablets”, 11 entries
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 9 studies
- Hepatic Insufficiency, 1 study
- Glomerulonephritis, IGA, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.